Segall Bryant & Hamill, LLC Glaukos Corp Transaction History

Segall Bryant & Hamill, LLC

$7.16 Billion
Q3 2024

A detailed history of Segall Bryant & Hamill, LLC transactions in Glaukos Corp stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 105,956 shares of GKOS stock, worth $15.3 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

105,956

Previous 110,283 3.92%

Holding current value

$15.3 Million

Previous $13.1 Million 5.76%

% of portfolio

0.19%

Previous 0.23%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$113.62 - $135.39 $491,633 - $585,832	-4,327 Reduced 3.92%	105,956 $13.8 Million
Q2 2024 Aug 14, 2024	BUY	$89.48 - $118.35 $268,529 - $355,168	3,001 Added 2.8%	110,283 $13.1 Million
Q1 2024 May 15, 2024	BUY	$76.4 - $96.33 $1.41 Million - $1.78 Million	18,484 Added 20.82%	107,282 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$59.53 - $85.11 $5.29 Million - $7.56 Million	88,798 New	88,798 $7.06 Million
Q1 2020 May 14, 2020	SELL	$25.53 - $70.14 $284,302 - $781,079	-11,136 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$54.18 - $65.64 $44,644 - $54,087	-824 Reduced 6.89%	11,136 $606,000
Q3 2019 Nov 12, 2019	BUY	$58.58 - $83.91 $2,870 - $4,111	49 Added 0.41%	11,960 $747,000
Q2 2019 Aug 14, 2019	BUY	$63.59 - $78.71 $3,179 - $3,935	50 Added 0.42%	11,911 $0
Q1 2019 May 15, 2019	BUY	$50.75 - $80.54 $14,463 - $22,953	285 Added 2.46%	11,861 $0
Q4 2018 Feb 15, 2019	SELL	$52.18 - $67.93 $30,838 - $40,146	-591 Reduced 4.86%	11,576 $650,000
Q3 2018 Nov 14, 2018	SELL	$38.13 - $68.37 $407,724 - $731,080	-10,693 Reduced 46.78%	12,167 $0
Q2 2018 Aug 08, 2018	BUY	$27.62 - $44.51 $631,393 - $1.02 Million	22,860 New	22,860 $0

Others Institutions Holding GKOS

# of Institutions

340

Shares Held

47.1M

Call Options Held

132K

Put Options Held

188K

View Full List

About GLAUKOS Corp

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.85B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

More about GKOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Glaukos Corp Transaction History